EZH2 and lung carcinoma: Since the inhibition of Ezh2 has recently been shown to amplify TNF-α–induced NF-κB signaling and inflammation in normal intestinal epithelium (Liu et al., 2017), it is plausible that our findings in lung cancer can be extended to other Kras-driven epithelial malignancies, such as pancreatic ductal carcinoma.